Researchers uncover up to 100 potential drug targets for cancer

May 15, 2018, University of Copenhagen
Researchers uncover up to 100 potential drug targets for cancer
In the study researchers used the technology mass spectrometry. Credit: University of Copenhagen

Protein researchers from the Novo Nordisk Foundation Center for Protein Research at the University of Copenhagen have used mass spectrometry-based proteomics to uncover a number of proteins that could play a critical role in propagating signals within cells that can lead to uncontrolled cell growth—one of the hallmarks of cancer.

The study, which has been published in Cell Reports, was conducted using mouse fibroblast . The behind the study believe the results may prove important to the development of new so-called tyrosine phosphatase-inhibiting drugs for patients suffering from different types , as well as other types of diseases such as Noonan syndrome.

Globally, cancer is one of the leading causes of death, according to the World Health Organization. In Denmark, one in every three Danes develops cancer at some point in their lives, according to statistics from the Danish Cancer Society.

The researchers focused on the protein communication and signalling that takes place inside the cells. Misregulation of protein signalling often leads to an increase in the production of tumours. By understanding the mechanisms and regulation of these signals, the researchers can specifically target the proteins responsible with drugs.

Using mass spectrometry proteomics to analyse the proteins of cells treated with various growth hormones in combination with advanced data analysis, the researchers discovered proteins that manipulate the communication processes inside the cells initiated by cell receptors and thus inhibit the development of cancer. When inhibited, the prominent protein Shp-2 caught the researchers' attention.

"This, in fact, leads to the deactivation of a very prominent cell growth pathway, which is the main pathway that people often try to target in ," Professor Jesper Velgaard Olsen from the research group explains.

At the beginning of the study, the researchers knew of a handful of proteins regulated by Shp-2. However, using the mass spectrometry analyses, the researchers discovered around 100 potential new targets, revealing a far more complexity than previously considered. Now, the researchers need to do further studies to determine the role and mechanisms of these proteins.

"Now, we are doing follow-up projects, looking specifically at leukaemia, where the cancer cells have mutations in these different receptors that can be regulated by Shp-2," says Postdoc Tanveer Singh Batth.

Cancer patients are often treated with , which block pathways inside the cells to inhibit tumour growth. However, many develop resistance to current clinical inhibitors; thus, there is a substantial need to find new proteins that can be used as drug targets.

The researchers' new discoveries can be used in the development of personalised medicine, in which preventive treatments can be targeted at the patients' personal DNA or protein expression profiles. "It will be a drug that can be used only in a world with personalised medicine, where it will not be given to for example all leukaemia patients, but only to those with mutations in one of the where we now know this Shp-2 operates," says Professor Jesper Velgaard Olsen.

Personalised medicine is gaining ground in Denmark. In 2016, the Government and the Danish Regions launched a strategy for efforts involving personalised medicine. A main part of the strategy is the establishment of a National Genome Center.

Explore further: Two drugs are better than one in fight against leukaemia

More information: Tanveer S. Batth et al. Large-Scale Phosphoproteomics Reveals Shp-2 Phosphatase-Dependent Regulators of Pdgf Receptor Signaling, Cell Reports (2018). DOI: 10.1016/j.celrep.2018.02.038

Related Stories

Two drugs are better than one in fight against leukaemia

March 8, 2018
Adelaide scientists have devised a way to enhance the effectiveness of a patient's leukaemia treatment by using a combination of drugs.

Switching on survival signalling to drive drug resistance

February 27, 2018
Researchers at Queen Mary University of London have discovered that the loss of a single protein- PHLDA1- is sufficient for the development of drug resistance to a type of targeted therapy in endometrial and HER2-positive ...

New knowledge on molecular mechanisms behind breast cancer

September 25, 2013
Researchers at University of Copenhagen have gained more insight into the molecular mechanisms of importance for, for example, cancer cell growth and metastasis. The research objective is improved and more targeted drugs. ...

Researchers find protein that marks difference between cancer and non-cancer cells

March 8, 2018
A discovery sheds light on how cancerous cells differ from healthy ones, and could lead to the development of new strategies for therapeutic intervention for difficult-to-treat cancers in the future.

New bowel cancer drug target discovered

October 17, 2017
Researchers at the Francis Crick Institute have discovered a new drug target for bowel cancer that is specific to tumour cells and therefore less toxic than conventional therapies.

Scientists reveal that new combination of clinically tested drugs inhibits growth of lung tumors

September 8, 2017
Research at the University of Southern Denmark has revealed that a new combination of clinically tested drugs inhibits the growth of tumours, thereby potentially improving patients' survival.

Recommended for you

Some brain tumors may respond to immunotherapy, new study suggests

December 10, 2018
Immunotherapy has proved effective in treating a number of cancers, but brain tumors have remained stubbornly resistant. Now, a new study suggests that a slow-growing brain tumor arising in patients affected by neurofibromatosis ...

Study finds higher risk of breast cancer for women after giving birth

December 10, 2018
Younger women who have recently had a child may have a higher risk of breast cancer than their peers of the same age who do not have children, according to a large-scale analysis co-led by a University of North Carolina Lineberger ...

A code for reprogramming immune sentinels

December 10, 2018
For the first time, a research team at Lund University in Sweden has successfully reprogrammed mouse and human skin cells into immune cells called dendritic cells. The process is quick and effective, representing a pioneering ...

Researchers develop personalized medicine tool for inherited colorectal cancer syndrome

December 10, 2018
An international team of researchers led by Huntsman Cancer Institute (HCI) at the University of Utah (U of U) has developed, calibrated, and validated a novel tool for identifying the genetic changes in Lynch syndrome genes ...

Study shows key enzyme linked to therapy resistance in deadly lung cancer

December 10, 2018
Researchers at The University of Texas MD Anderson Cancer Center have identified a link between an enzyme tied to cancer formation and therapy resistance in patients with epidermal growth factor receptor (EGFR)-mutant non-small ...

Potential seen for tailoring treatment for acute myeloid leukemia

December 8, 2018
Advances in rapid screening of leukemia cells for drug susceptibility and resistance are bringing scientists closer to patient-tailored treatment for acute myeloid leukemia (AML).

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.